4 results
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…
Evaluation of the feasibility of sentinel node detection by PET-CT lymphoscintigraphy
The objective of this study is to evaluate the safety and efficacy of the MGuard* Prime stent in the treatment of de novo stenotic lesions in coronary arteries in patients undergoing primary PCI due to acute STEMI as compared with BMS or DES in the…
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…